– 40 Percent of Patients Treated with Mitapivat Achieved a Sustained Hemoglobin Increase of ≥1.5 g/dL Compared to 0 Placebo Patients (p
Agios Announces the Phase 3 ACTIVATE Trial of Mitapivat Achieved Its Primary Endpoint in Adults with Pyruvate Kinase Deficiency Who Are Not Regularly Transfused
On 6ix: 6ix.com/news/agios-announces-the-phase-3-activate-trial-of-mitapivat-achieved-its-primary-endpoint
Watch Agios Pharmaceuticals' latest callAgios Pharmaceuticals (NASDAQ:AGIO) Q2 2026 Earnings Call · Replay · Jul 30Read the transcript of Agios Pharmaceuticals (NASDAQ:AGIO) Q2 2026 Earnings CallAgios Pharmaceuticals' next earnings callAgios Pharmaceuticals (NASDAQ:AGIO) Q3 2026 Earnings Call · Nov 5, 2026 at 8:00 AM ESTRegister
Agios Pharmaceuticals, Inc. on 6ix
Earlier from Agios Pharmaceuticals
- Agios Launches Anemia ID, a No-Cost Genetic Testing Program for Hereditary Anemias
- Agios to Present at the Piper Sandler 32nd Annual Virtual Healthcare Conference on Wednesday, December 2, 2020
- Agios Announces FDA Orphan Drug Designation Granted to Mitapivat for Treatment of Sickle Cell Disease
- Agios Reports Business Highlights and Third Quarter 2020 Financial Results
- Agios to Present Broad Set of Clinical and Translational Data for Oncology and Rare Genetic Disease Programs at the Virtual 2020 ASH Annual Meeting
Later from Agios Pharmaceuticals
- Agios Announces Updated Data from Phase 1 Study of Mitapivat, First-in-Class PKR Activator, in Sickle Cell Disease
- Agios to Focus on Developing and Commercializing Innovative Treatments for Genetically Defined Diseases and Sell Its Oncology Business to Servier for Up to $2 Billion Plus Royalties
- Agios to Present at the 39th Annual J.P. Morgan Healthcare Conference on Monday, January 11, 2021
- Agios Highlights 2021 Milestones to Accelerate and Expand Its Genetically Defined Disease Portfolio and Drive Near- and Long-Term Value Creation
- Agios Presents Final Data from Phase 3 ClarIDHy Study of TIBSOVO® (ivosidenib tablets) in Patients with Previously Treated IDH1-Mutant Cholangiocarcinoma
Follow Agios Pharmaceuticals into a list and get an email when it puts out news.
Follow Agios Pharmaceuticals